#BEGIN_DRUGCARD DB00689

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Well absorbed following oral administration.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
CEG
Cefaloglicina [INN-Spanish]
Cefaloglycin
Cefaloglycine [INN-French]
Cefaloglycinum [INN-Latin]
Cephaloglycin anhydrous
Cephaloglycine
Cephaoglycin acid
D-Cephaloglycine
Kafocin
Kefglycin

# CAS_Registry_Number:
3577-01-3

# ChEBI_ID:
Not Available

# Chemical_Formula:
C18H19N3O6S

# Chemical_IUPAC_Name:
(6R,7R)-3-[(acetyloxy)methyl]-7-[(2R)-2-amino-2-phenylacetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A cephalorsporin antibiotic. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Bacterial Agents
Cephalosporins

# Drug_Interactions:
Probenecid	Probenecid may increase the serum level of cephaloglycin.

# Drug_Reference:
2133431	Tune BM, Hsu CY: The renal mitochondrial toxicity of beta-lactam antibiotics: in vitro effects of cephaloglycin and imipenem. J Am Soc Nephrol. 1990 Nov;1(5):815-21.
2930580	Tune BM, Fravert D, Hsu CY: Oxidative and mitochondrial toxic effects of cephalosporin antibiotics in the kidney. A comparative study of cephaloridine and cephaloglycin. Biochem Pharmacol. 1989 Mar 1;38(5):795-802.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
154 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Cephaloglycin

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26)/t12-,13-,17-/m1/s1

# InChI_Key:
InChIKey=FUBBGQLTSCSAON-PBFPGSCMSA-N

# Indication:
For treatment of severe infections caused by susceptible bacteria.

# KEGG_Compound_ID:
C13440

# KEGG_Drug_ID:
D01949

# LIMS_Drug_ID:
689

# Mechanism_Of_Action:
The bactericidal activity of cephaloglycin results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).

# Melting_Point:
237 dec Â°C

# Molecular_Weight_Avg:
405.425

# Molecular_Weight_Mono:
405.099456045

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164781027

# Pharmacology:
Cephaloglycin is an antibiotic related to cephalosporin but no longer in common use. It is an orally absorbed derivative of cephalosporin C.

# Predicted_LogP_Hydrophobicity:
0.54

# Predicted_LogS:
-3.4

# Predicted_Water_Solubility:
1.48e-01 g/l

# Primary_Accession_No:
DB00689

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
19150

# PubChem_Substance_ID:
46506850

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00858

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.

# Update_Date:
2013-02-08 16:19:33 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Cephaloglycin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
7565098	Lepage S, Lakaye B, Galleni M, Thamm I, Crine M, Groslambert S, Frere JM: Saturation of penicillin-binding protein 1 by beta-lactam antibiotics in growing cells of Bacillus licheniformis. Mol Microbiol. 1995 Apr;16(2):365-72.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
pbpA

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7174

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
PbpA

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q65HB5

# Drug_Target_1_SwissProt_Name:
Q65HB5_BACLD

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB00689
